Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

A patient with alopecia had hair regrowth with tofacitinib but developed a skin reaction, choosing to continue the treatment despite the side effect.

In this retrospective study, anti-tuberculous agents, likely rifampicin, were effective adjunctive therapies for a chalazion, coinciding with spontaneous drainage in a patient with rosacea.

This review outlines current treatment strategies for trichotillomania, noting cognitive-behavioral therapy's success, while highlighting the promise and limitations of various pharmacological options.

This phase I study reported that ETC-159, targeting Wnt signalling, showed tolerable safety profiles at doses that inhibit its pathway, though bone turnover markers increased, warranting early and regular monitoring. No tumor responses were observed, but two patients achieved stable disease for several cycles.

This article discusses treatments for androgenic manifestations using cyproterone acetate alone or with estrogens, but it does not provide new clinical results.

In this open-label trial, tofacitinib showed dramatic clinical responses in most patients with moderate-to-severe alopecia areata, supporting further research into JAK inhibitors for this condition.

This case series found that oral tofacitinib treatment in eight adolescents with alopecia universalis led to significant regrowth of hair, though relapse is likely after stopping therapy.

In this clinical trial, adding topical calcipotriol to intralesional triamcinolone acetonide significantly increased hair regrowth efficacy in scalp alopecia areata patches compared to steroids alone, but not in beard patches, with a lower incidence of atrophy observed.

This study observed that discontinuation rates due to side effects were similar for penicillamine and tiopronin among cystinuria patients, and switching to the alternative agent was beneficial for half of those experiencing issues.

This study highlights that while there are no FDA- or ANVISA-approved treatments for children with alopecia areata, JAK inhibitors are emerging as a promising therapeutic option for this population.

In this study, authors present a case where a 26-year-old patient with alopecia areata experienced relapse after initially responding to Tofacitinib, mitigated by corticosteroids, highlighting challenges and potential insights into the treatment and pathogenesis of the condition.

In this case report, a 42-year-old woman with cutaneous dermatomyositis showed significant improvement, including reduction of erythema, pruritus, and scaling, after starting JAK inhibitor tofacitinib, especially when conventional systemic treatments failed and intravenous immune globulin wasn't viable.

This review discusses the role of contraceptives in dermatology, particularly for acne treatment and managing patients on teratogens, but reports no new clinical results.

In this study, researchers found that combining cryotherapy with triamcinolone injections is equally effective as triamcinolone alone for treating patchy alopecia areata on the scalp and face, with no significant difference in outcomes between the two methods.

In this case study, a 5-year-old girl with alopecia areata and atopic dermatitis that were unresponsive to previous treatments achieved substantial improvement with long-term tofacitinib, highlighting its potential safety and efficacy in managing both conditions concurrently.

This study found that cortexolone 17α-propionate showed strong topical antiandrogenic activity, outperforming progesterone and several known antiandrogens, but lacked systemic antiandrogenic effects in animal models.

In this randomized control trial, researchers reported that topical calcipotriol was more effective than topical tacrolimus in promoting hair growth for patients with alopecia areata over a 6-month period, with a statistically significant difference in efficacy.

This study found that tofacitinib shows reasonable effectiveness for treating alopecia areata with mild adverse effects, although more large-scale randomized trials are needed to fully assess its safety and efficacy.

This study found that Betamethasone was more effective than Tacrolimus and soft paraffin in promoting hair regrowth in patients with mild to moderate patchy alopecia areata.

In this case report, a 39-year-old woman's symptoms from dermatomyositis–systemic lupus erythematosus overlap syndrome improved only after she was treated with tofacitinib.

This study confirms an association between TNF-α antagonist exposure and alopecia, indicating a class effect among the medications examined.

This article discusses using topical tretinoin with intralesional triamcinolone acetonide for alopecia areata in northern Saudi Arabia, but it reports no new clinical findings.

In this study, researchers at Jawaharlal Nehru Medical College are comparing the effectiveness and side effects of Adapalene gel (0.1%) and Tazarotene gel (0.05%) in acne treatment among patients aged 12-35, with assessments every 4, 8, and 12 weeks. Results are not reported yet.

This study found that ALRN-6924, a clinical-stage dual inhibitor, can selectively protect human scalp hair follicles from paclitaxel-induced toxicity and damage by inducing transient cell cycle arrest in healthy cells without affecting cancer cells, potentially reducing chemotherapy-induced alopecia.

This study found that among patients with twenty-nail dystrophy, those treated with oral cyclosporine in combination with a dietary supplement showed significantly better improvement in nail condition and quality of life than those treated with the supplement alone.

This source discusses that while oral JAK inhibitors are used for treating lichen planopilaris and frontal fibrosing alopecia, they carry significant risk of adverse events; two cases showed promising results using tofacitinib cream as a safer topical alternative.

This article discusses alopecia areata, highlighting its autoimmune nature and the lack of FDA-approved treatments, without providing new research findings.

This study found that intralesional methotrexate and triamcinolone acetonide have similar efficacy for localized alopecia areata in adults, but differ in safety profiles, with methotrexate associated with hyperpigmentation and triamcinolone with atrophy.